Phathom Historical Cash Flow
| PHAT Stock | USD 5.99 0.35 5.52% |
Analysis of Phathom Pharmaceuticals cash flow over time is an excellent tool to project Phathom Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 208.7 M or Depreciation of 376.8 K as it is a great indicator of Phathom Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Phathom Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Phathom Pharmaceuticals is a good buy for the upcoming year.
Phathom |
About Phathom Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Phathom balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Phathom's non-liquid assets can be easily converted into cash.
Phathom Pharmaceuticals Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Capital Expenditures
Capital Expenditures are funds used by Phathom Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Phathom Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Phathom Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Phathom Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phathom Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.At this time, Phathom Pharmaceuticals' Change In Cash is comparatively stable compared to the past year. Other Cashflows From Financing Activities is likely to gain to about 208.7 M in 2025, whereas Net Borrowings is likely to drop slightly above 61.2 M in 2025.
| 2022 | 2023 | 2024 | 2025 (projected) | Other Non Cash Items | 21.0M | 32.1M | 28.9M | 25.5M | Depreciation | 620K | 575K | 661.3K | 376.8K |
Phathom Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Phathom Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Phathom Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (1.0M) | (328K) | (1.0M) | (1.6M) | (1.9M) | (2.0M) | |
| Change In Cash | 43.7M | (104.2M) | (27.5M) | 228.4M | 262.6M | 275.8M | |
| Net Borrowings | 113.2M | 25M | 42.8M | 95.4M | 109.8M | 61.2M | |
| Free Cash Flow | (70.7M) | (148.9M) | (147.6M) | (139.2M) | (125.3M) | (131.6M) | |
| Change In Working Capital | 51.7M | (27.5M) | 5.4M | (13.6M) | (12.3M) | (11.7M) | |
| Begin Period Cash Flow | 243.8M | 287.5M | 183.4M | 155.9M | 179.3M | 159.8M | |
| Other Cashflows From Financing Activities | 629K | 1.9M | 95.4M | 172.8M | 198.7M | 208.7M | |
| Depreciation | 323K | 521K | 620K | 575K | 661.3K | 376.8K | |
| Other Non Cash Items | 1.6M | 5.4M | 21.0M | 32.1M | 28.9M | 25.5M | |
| Capital Expenditures | 1.0M | 328K | 1.0M | 1.6M | 1.5M | 1.4M | |
| Total Cash From Operating Activities | (69.7M) | (148.6M) | (146.5M) | (137.6M) | (123.8M) | (130.0M) | |
| Change To Operating Activities | (11.8M) | 27.7M | (17.7M) | (3.2M) | (2.9M) | (2.8M) | |
| Issuance Of Capital Stock | 88.8M | 0.0 | 24.6M | 155.5M | 178.8M | 187.7M | |
| Net Income | (129.1M) | (143.9M) | (197.7M) | (201.6M) | (181.4M) | (190.5M) | |
| Total Cash From Financing Activities | 114.5M | 44.7M | 120.0M | 367.6M | 422.7M | 443.9M | |
| End Period Cash Flow | 287.5M | 183.3M | 155.9M | 384.3M | 441.9M | 230.2M | |
| Change To Netincome | 227.7M | 6.1M | 18.6M | 43.0M | 38.7M | 47.3M | |
| Change To Liabilities | 2.3M | 24.0M | (9.6M) | 8.7M | 10.0M | 5.6M | |
| Stock Based Compensation | 5.8M | 16.8M | 24.1M | 45.0M | 51.8M | 54.4M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.